Dr. Cristina Rondinone has served as member of our Board since June 2018. She brings more than 20 years of experience in the biopharmaceutical industry with a record of successfully leading the discovery and development of numerous molecules. Since June of 2020, Dr. Rondinone has consulted for pharmaceutical and biotechnology companies at CMR Pharma Consulting. Prior to this role, she served as President of Cellarity Inc., and for eight years she held roles of increasing responsibility at AstraZeneca and Medimmune, serving more recently as Senior Vice President and Head of Cardiovascular, Renal, and Metabolic Diseases. During her tenure, she initiated the therapeutic area and led cross-functional teams responsible for strategy, growth, and advancement of the portfolio. She led the way to advance a number of programs to Phase 2b trials in record time. Prior to Medimmune, Dr. Rondinone held leadership positions at Hoffmann-La Roche as well as at Abbott Laboratories

Before joining the pharmaceutical industry, she was Associate Professor (Docent) of Molecular Medicine at the University of Gothenburg in Sweden. Dr. Rondinone received her Ph.D. in Biological Sciences from the University of Buenos Aires. Her postdoctoral training was at the Laboratory of Cellular and Developmental Biology at NIDDK, National Institutes of Health, USA.

Dr. Rondinone has authored more than 80 peer-reviewed publications and currently holds five patents. She was also editor of the book Therapeutic Applications of RNAi. Additionally, she is a member of the Scientific Advisory Board for Axcella and the Keystone Symposia as well as a member of the Royal Academy of Pharmacy in Spain.